Fmr LLC Liquidia Corp Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Liquidia Corp stock. As of the latest transaction made, Fmr LLC holds 914,488 shares of LQDA stock, worth $21.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

914,488

Previous 920,239 0.62%

Holding current value

$21.7 Million

Previous $13.6 Million 16.05%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$11.99 - $19.3 $68,954 - $110,994	-5,751 Reduced 0.62%	914,488 $11.4 Million
Q1 2025 May 12, 2025	BUY	$11.36 - $16.5 $10.2 Million - $14.8 Million	899,606 Added 4360.03%	920,239 $13.6 Million
Q4 2024 Feb 13, 2025	BUY	$9.82 - $11.8 $185,568 - $222,984	18,897 Added 1088.54%	20,633 $242,000
Q3 2024 Nov 13, 2024	BUY	$8.9 - $14.11 $898 - $1,425	101 Added 6.18%	1,736 $17,000
Q2 2024 Aug 13, 2024	BUY	$11.96 - $15.71 $657 - $864	55 Added 3.48%	1,635 $19,000
Q1 2024 May 13, 2024	BUY	$11.35 - $16.73 $2,167 - $3,195	191 Added 13.75%	1,580 $23,000
Q4 2023 Feb 13, 2024	BUY	$5.77 - $12.19 $2,192 - $4,632	380 Added 37.66%	1,389 $16,000
Q3 2023 Nov 13, 2023	SELL	$6.27 - $8.15 $3,674 - $4,775	-586 Reduced 36.74%	1,009 $6,000
Q2 2023 Aug 11, 2023	SELL	$6.63 - $9.9 $523 - $782	-79 Reduced 4.72%	1,595 $12,000
Q1 2023 May 11, 2023	BUY	$5.72 - $7.91 $3,117 - $4,310	545 Added 48.27%	1,674 $11,000
Q4 2022 Feb 13, 2023	SELL	$4.68 - $6.54 $449 - $627	-96 Reduced 7.84%	1,129 $7,000
Q3 2022 Nov 10, 2022	BUY	$3.73 - $8.39 $1,533 - $3,448	411 Added 50.49%	1,225 $7,000
Q2 2022 Aug 12, 2022	BUY	$3.37 - $7.55 $2,733 - $6,123	811 Added 27033.33%	814 $3,000
Q1 2022 May 13, 2022	BUY	$5.14 - $7.38 $15 - $22	3 New	3 $0

Others Institutions Holding LQDA

# of Institutions

210

Shares Held

47.5M

Call Options Held

1.61M

Put Options Held

1.15M

View Full List

About Liquidia Corp

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $1.53B
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

More about LQDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account